کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9296378 | 1233528 | 2005 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TNFNF-κBTetrathiomolybdateCK-MBTGFALTinterferon - اینترفرونIFN - اینترفرون هاinterleukin - اینترلوکینtransforming growth factor - تبدیل فاکتور رشدanalysis of variance - تحلیل واریانسANOVA - تحلیل واریانس Analysis of varianceEnzyme-linked immunosorbent assay - تست الیزاELISA - تست الیزاtumor necrosis factor - فاکتور نکروز تومورnuclear factor-κB - فاکتور هسته ای κBlactic dehydrogenase - لاکتات دهیدروژنازLDH - لاکتات دهیدروژناز به صورت مختصر شده LDH Creatine kinase - کراتین کیناز
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice](/preview/png/9296378.png)
چکیده انگلیسی
Cardiac toxicity is the limiting factor in therapy with doxorubicin, an otherwise useful cancer drug. In this article we detail our study of a mouse model of doxorubicin-induced cardiac toxicity in which, after 4 days' treatment, doxorubicin caused marked increases in plasma concentrations of creatine kinase, lactic dehydrogenase, and troponin I, indicators of cardiac injury; marked increases in the plasma concentrations of tumor necrosis factor-α and interleukin-1β, both inflammatory cytokines; and a marked increase in the plasma concentration of interleukin-2, an indicator of cytotoxic T-cell activation. Therapy with tetrathiomolybdate, designed to limit copper availability, eliminated almost all of the increases of these six parameters in plasma. The marked protection against cardiac injury by doxorubicin in tetrathiomolybdate-treated animals suggests that tetrathiomolybdate would be of use clinically in helping prevent doxorubicin toxicity in patients. In other preclinical work, it has been shown that tetrathiomolybdate potentiates the chemotherapeutic effect of doxorubicin in cancer, so a double benefit might accrue clinically from the combined use of tetrathiomolybdate and doxorubicin. The mechanism by which tetrathiomolybdate protects against doxorubicin toxicity is of considerable interest. Our working hypothesis, based on the inhibition of interleukin-2 by tetrathiomolybdate as shown here, is that tetrathiomolybdate interrupts the inflammatory cascade at the activated-T-lymphocyte stage.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Laboratory and Clinical Medicine - Volume 146, Issue 5, November 2005, Pages 299-303
Journal: Journal of Laboratory and Clinical Medicine - Volume 146, Issue 5, November 2005, Pages 299-303
نویسندگان
Guoqing Hou, Robert Dick, Gerald D. Abrams, George J. Brewer,